By suppressing NF-κB-induced PD-L1 expression on tumor cells, these therapies can enhance T-cell activity against tumors, through a dual approach by directly inhibiting tumor cell survival mechanisms while boosting anti-tumor immunity (Lim et al., 2016). This evidence concerns the gene CD274 and neoplasm.